Cellectis (CLLS) Share-based Compensation Growth (3y) (2018 - 2026)
Cellectis (CLLS) Share-based Compensation Growth (3y) (2018 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Stock Comp. Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
- |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
- |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
4.80% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
10.78% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Cellectis |
17.40 Bn |
17.21 Bn |
- |
0.88% |
| Date | Value |
|---|
| Mar 31, 2026 |
0.88% |
| Dec 31, 2025 |
79.81% |
| Sep 30, 2025 |
6.43% |
| Jun 30, 2025 |
-13.94% |
| Mar 31, 2025 |
-25.03% |
| Dec 31, 2024 |
-22.96% |
| Sep 30, 2024 |
-53.25% |
| Jun 30, 2024 |
-40.75% |
| Mar 31, 2024 |
209.22% |
| Dec 31, 2023 |
54.14% |
| Sep 30, 2023 |
-40.69% |
| Jun 30, 2023 |
-29.28% |
| Mar 31, 2023 |
-30.26% |
| Dec 31, 2022 |
-62.07% |
| Sep 30, 2022 |
-44.97% |
| Jun 30, 2022 |
-33.11% |
| Mar 31, 2022 |
-23.10% |
| Dec 31, 2021 |
-37.85% |
| Sep 30, 2021 |
-12.04% |
| Jun 30, 2021 |
-23.76% |
